Kainga IPHASE DS8201a

IPHASE DS8201a

Whakaahuatanga Poto:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

WHAKAPAKI NEI Tāpirihia ki te kaata hokohoko

Taipitopito Hua

Tohu Hua

Whakaahuatanga hua Ko te DS-8201a, e mohiotia ana ko trastuzumab deruxtecan (T-DXd), he antibody-drug conjugate (ADC) i hangaia mo te maimoatanga o te HER2-nga mate pukupuku pai. Ka honoa he HER2-whakaaro i te antibody monoclonal (he rite ki te trastuzumab) me te aukati topoisomerase I kaha (deruxtecan) hei utunga cytotoxic. Ko te rongoa e tuku tika ana i te chemotherapy ki nga pūtau mate pukupuku e whakaatu ana i te HER2, me te whakapai ake i te whaihuatanga i te wa e whakaiti ana i te kino ki nga pūtau noa.

Kāwai:
Cathepsin
Te nama take:
015200.01
Rahi Waeine:
50uL,2mg/mL
Kopa:
N/A
Momo:
N/A
Nga tikanga rokiroki me te kawe:
Rokiroki i te -70°C. Ka tukuna te huka maroke.